Stock Analysis
GoHealth (NASDAQ:GOCO) Full Year 2022 Results
Key Financial Results
- Revenue: US$631.7m (down 41% from FY 2021).
- Net loss: US$148.7m (loss narrowed by 22% from FY 2021).
- US$17.61 loss per share (improved from US$26.80 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
GoHealth Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 31%. Earnings per share (EPS) also missed analyst estimates significantly.
Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Insurance industry in the US.
Performance of the American Insurance industry.
The company's shares are down 24% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 3 warning signs for GoHealth that you should be aware of.
What are the risks and opportunities for GoHealth?
GoHealth, Inc. operates as a health insurance marketplace and Medicare focused digital health company in the United States.
Rewards
Revenue is forecast to grow 15.21% per year
Risks
Shareholders have been diluted in the past year
Volatile share price over the past 3 months
Currently unprofitable and not forecast to become profitable over the next 3 years
Further research on
GoHealth
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.